SFM
JSPR icon

Sphera Funds Management’s Jasper Therapeutics JSPR Stock Holding History

Sphera Funds Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-485,401
Closed -$888K – 106
2025
Q4 		$888K Sell
485,401
-144,069
-23% -$289K 0.17% 88
2025
Q3 		$1.5M Buy
629,470
+614,799
+4,191% +$1.86M 0.32% 81
2025
Q2 		$81.4K Sell
14,671
-107,346
-88% -$529K 0.02% 109
2025
Q1 		$525K Sell
122,017
-13,703
-10% -$91.2K 0.12% 105
2024
Q4 		$2.9M Sell
135,720
-53,550
-28% -$1.11M 0.52% 66
2024
Q3 		$3.56M Sell
189,270
-264,957
-58% -$5.28M 0.57% 52
2024
Q2 		$10.3M Sell
454,227
-51,015
-10% -$1.22M 1.41% 24
2024
Q1 		$14.8M Buy
505,242
+433,936
+609% +$7.71M 2.08% 10
2023
Q4 		$5.63M Sell
71,306
-497,407
-87% -$3.34M 0.91% 44
2023
Q3 		$3.98M Buy
568,713
+141,312
+33% +$1.72M 0.73% 49
2023
Q2 		$5.86M Buy
427,401
+23,000
+6% +$342K 0.91% 43
2023
Q1 		$7.32M Buy
+404,401
New +$7.48M 1.22% 27

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Sphera Funds Management's JSPR Position: Q1 2026 in Review

Sphera Funds Management sold out of Jasper Therapeutics (JSPR) in Q1 2026, closing a stake of 485,401 shares — an estimated $888K sold.

Sphera Funds Management first reported a position in JSPR in Q1 2023 and held it in 12 quarters. The position peaked at $14.8M in Q1 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Sphera Funds Management reported no remaining Jasper Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sphera Funds Management sold 485,401 Jasper Therapeutics shares in Q1 2026, an estimated $888K.
  • Sphera Funds Management first reported a position in Jasper Therapeutics in Q1 2023 and held it in 12 quarters.
  • Sphera Funds Management's Jasper Therapeutics position peaked at $14.8M in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.